Brakewood Harold Eugene 4

What Happened

• Harold E. Brakewood, Chief Business Officer of Immuneering Corp (IMRX), was granted a derivative award on Feb 3, 2026 for 140,000 shares. The filing reports an acquisition price of $0.00 (derivative award), with total reported value $0.

Key Details

• Transaction date: 2026-02-03; Filing date: 2026-02-05 (filed timely).
• Transaction type: Grant / award of a derivative (SEC code A).
• Shares involved: 140,000 (derivative award / option-style grant).
• Price reported: $0.00 per share for the award; total reported value $0.
• Vesting: Vests and becomes exercisable in equal monthly installments over a four-year period commencing Feb 1, 2026; fully vested and exercisable on Jan 1, 2030 (per footnote).
• Shares owned after transaction: Not specified in the filing.

Context

• This was a grant of a derivative award (an option-style award) rather than an immediate purchase of common stock. Such grants are common for executive compensation and do not by themselves indicate a purchase or sale of shares on the open market. The vesting schedule means Brakewood must remain employed/meet vesting conditions to obtain exercisable rights over time.